BeVigilantTM OraFusion System
Granted FDA Breakthrough Device Designation
The BeVigilantTM OraFusion System is Not Available For Sale in the U.S.
The BeVigilantTM OraFusion System easily identifies the presence of biomarkers associated with oral cancer in 15 minutes or less.
The BeVigilant™ OraFusion System is CE-Marked and available in select markets outside the United States.
BeVigilantTM OraFusion System
With the BeVigilantTM OraFusion System, clinicians can get a simple and accurate* assessment to aid in the early detection of oral cancer. The platform provides a semi-quantitative result at the point–of–care, reporting low, moderate or elevated levels of risk associated with oral cancer. Learn how it benefits dentists and their patients:
BeVigilantTM OraFusion Test Output: Biomarkers + Clinical Risk Factors
How the BeVigilantTM OraFusion System Works
BeVigilantTM OraFusion System is an easy-to-use, accurate*, semi-quantitative tool for frontline healthcare clinicians assessing potentially at-risk patients for oral cancer.
The BeVigilantTM Reader is an advanced immunochromatography reader which captures the test data and provides the results during the patient’s visit.
Created to improve outcomes through earlier intervention, the BeVigilantTM OraFusion System is
ACCURATE*
Using multiple biomarkers in conjunction with clinical risk factors provides an accurate risk assessment
NON-INVASIVE
Simple saliva test
Fast
Results in just 15 minutes or less
The BeVigilantTM OraFusion System is CE-Marked and available in select markets outside the United States. Interested in learning more about the technology’s availability in your market?
The BeVigilantTM OraFusion System is a value-added offering allowing clinicians to integrate easily into their practice as part of the patients’ regular care. Schedule a demo to discover if the BeVigilantTM OraFusion System is right for your practice.
*Clinical Data on File